Pharma BD Deal Intelligence
Valeant snaps up Sanofi's Dermik for $425M, adding Sculptra, BenzaClin and Carac and reinforcing its aggressive dermatology roll-up strategy under CEO Mike…
FTC required Valeant to divest topical 5-FU, BenzaClin/clindamycin-BPO generic rights, and a wrinkle treatment to Mylan and Spear Pharmaceuticals as a…
Valeant's twin acquisitions of Ortho and Dermik dramatically expand its prescription dermatology footprint, but FTC-mandated divestitures temper the strategic…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi divested its US/Canada dermatology unit Dermik to Valeant for ~$425M cash. Portfolio included Sculptra, BenzaClin, Carac. Closed December 16, 2011 with FTC-mandated divestitures.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) (this deal) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2011 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals